精神药理学未来:在研2/3期试验与降低新药试验风险趋势的批判性评估
本文综述了精神分裂症、双相障碍、重性抑郁障碍、焦虑与创伤相关障碍、物质使用障碍及痴呆等领域正在接受2期或3期试验、具有创新作用机制的最有前景药物,并讨论了已上市药物用于新精神科适应症的重定位及多巴胺、去甲肾上腺素和5-羟色胺受体调节的变体。文章批判性分析了新药开发与试验中需深入考虑的临床试验参数,指出纳入/排除标准与评定量表不充分和不精确、试验参与者选择欠佳、导致安慰剂效应偏大或增大的多重因素以及统计分析问题等阻碍,并提出应据此降低新药或已知药物新适应症试验项目的风险以提高成功率。
要点
- 综述梳理多类精神障碍在研2/3期创新机制药物及已上市药物重定位。
- 纳入/排除标准与评定不精确、参与者选择欠佳可威胁试验成功。
- 多重因素造成安慰剂效应偏大或增大及统计分析问题需在试验设计中考虑。
核心结论
- 过去七十年药物治疗虽有相当进展,但许多精神障碍仍治疗不充分,部分源于对病理生理认识有限、缺乏生物标志物用于分层和个体化选例,以及单药或联合/增效治疗所针对的作用机制数量仍有限。
- 开发与测试新药面临多重挑战,包括纳入/排除标准和评定的不充分与不精确、临床试验参与者选择欠佳、导致安慰剂效应偏大或增大的多重因素以及统计分析问题。
- 应考虑上述信息以降低新药或已知药物用于新精神科适应症的试验项目风险,提高成功机会。
研究设计与样本
- 本文为对正在进行的2/3期试验及当前旨在降低新药试验项目风险的一些趋势的批判性评估。
- 文章概述了精神分裂症、双相障碍、重性抑郁障碍、焦虑与创伤相关障碍、物质使用障碍和痴呆中具有创新作用机制、正在接受2期或3期测试的最有前景药物。
- 文章还考虑了已上市药物用于新精神科适应症的有前景重定位,以及多巴胺、去甲肾上腺素和5-羟色胺受体功能调节的变体。
主要发现
- 许多精神障碍仍治疗不充分,部分由于对病理生理知识有限及缺乏生物标志物来分层和个体化选择患者。
- 单药或联合/增效治疗所针对的作用机制数量仍然有限,且多种挑战威胁新药的成功开发与测试。
- 威胁新药开发与测试成功的阻碍和风险包括纳入/排除标准与评定不充分和不精确、试验参与者选择欠佳、多重因素导致安慰剂效应偏大或增大以及统计分析问题。
临床怎么用
- 在开发与测试治疗精神障碍的新药时,需深入考虑临床试验参数,包括纳入/排除标准、评定工具和参与者选择。
- 应关注安慰剂效应偏大或增大的多重影响因素及统计分析问题,以降低新药或已知药物新适应症试验项目的风险。
- 上述试验设计考量可用于提高新药开发与测试的成功机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite considerable progress in pharmacotherapy over the past seven decades, many mental disorders remain insufficiently treated. This situation is in part due to the limited knowledge of the pathophysiology of these disorders and the lack of biological markers to stratify and individualize patient selection, but also to a still restricted number of mechanisms of action being targeted in monotherapy or combination/augmentation treatment, as well as to a variety of challenges threatening the successful development and testing of new drugs. In this paper, we first provide an overview of the most promising drugs with innovative mechanisms of action that are undergoing phase 2 or 3 testing for schizophrenia, bipolar disorder, major depressive disorder, anxiety and trauma-related disorders, substance use disorders, and dementia. Promising repurposing of established medications for new psychiatric indications, as well as variations in the modulation of dopamine, noradrenaline and serotonin receptor functioning, are also considered. We then critically discuss the clinical trial parameters that need to be considered in depth when developing and testing new pharmacological agents for the treatment of mental disorders. Hurdles and perils threatening success of new drug development and testing include inadequacy and imprecision of inclusion/exclusion criteria and ratings, sub-optimally suited clinical trial participants, multiple factors contributing to a large/increasing placebo effect, and problems with statistical analyses. This information should be considered in order to de-risk trial programmes of novel agents or known agents for novel psychiatric indications, increasing their chances of success.
引用
- Correll CU, Solmi M, Cortese S, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023. PMID: 36640403. doi:10.1002/wps.21056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。